DNA — Ginkgo Bioworks Holdings, Inc.
—
NYSE ·
Health Care ·
Biotechnology ·
CIK 1830214 ·
Last close
$8.69
Market Cap
$463.71M
52W High
$10.64
52W Low
$5.37
ADV30
1,253,263
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 19,474,000 | 16,376,000 | -71,374,000 | -82,587,000 | 1,033,075,000 | 143,864,000 | 589,922,000 |
| Dec 2025 | 33,396,000 | 26,095,000 | -70,046,000 | -80,751,000 | 1,119,696,000 | 167,202,000 | 611,106,000 |
| Sep 2025 | 38,837,000 | 26,035,000 | -88,272,000 | -80,755,000 | 1,189,165,000 | 111,065,000 | 629,382,000 |
| Jun 2025 | 49,604,000 | 34,782,000 | -61,867,000 | -60,300,000 | 1,231,009,000 | 203,566,000 | 618,057,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-174,743,000
Investing CF
$-18,473,000
Financing CF
$17,963,000
CapEx
$-9,598,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.62
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-6,232,907,000
Inventory
—
Receivables
$20,269,000
ST Investments
$229,592,000
EBIT TTM
$-301,279,000
Pretax Income TTM
$-298,870,000
Interest Exp TTM
—
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$151,399,008
EBITDA
$-262,492,992
Free Cash Flow
$-77,930,000
Enterprise Value
$604,913,856
Total Cash
$373,456,000
Total Debt
$410,700,000
Shares Out
53,361,141
Trailing EPS
$-5.38
Book Value
$7.19
ROE
-56.0%
ROA
-16.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 170,155,000 | -303,880,000 | -312,763,000 | 1,119,696,000 | 611,106,000 | — | -171,059,000 |
| Dec 2024 | 227,043,000 | -487,727,000 | -547,029,000 | 1,377,449,000 | 661,391,000 | — | -319,585,000 |
| Dec 2023 | 251,455,000 | -768,196,000 | -892,869,000 | 1,665,342,000 | 568,190,000 | — | -295,500,000 |
| Dec 2022 | 477,706,000 | -2,208,952,000 | -2,104,929,000 | 2,539,321,000 | 803,044,000 | — | -252,198,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.21
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| FDMT | 4D Molecular Therapeutics, Inc. | $455.33M | $8.71 | — |
| STRO | SUTRO BIOPHARMA, INC. | $453.70M | $27.38 | — |
| OCGN | Ocugen, Inc. | $453.62M | $1.34 | — |
| AUTL | Autolus Therapeutics plc | $447.12M | $1.68 | — |
| KYTX | Kyverna Therapeutics, Inc. | $523.45M | $8.61 | — |
News headlines (Yahoo Finance, 1h cache)
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery
2026-05-26 16:33 · Yahoo
Ginkgo Bioworks Holdings Inc (DNA): What’s the Future of Autonomous Lab?
2026-05-22 12:36 · Yahoo
The Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Sales Forecasts
2026-05-13 11:41 · Yahoo
How The Ginkgo Bioworks (DNA) Story Is Shifting After The Biosecurity Divestiture And Target Cut
2026-05-11 19:13 · Yahoo
Ginkgo Bioworks Q1 Earnings Call Highlights
2026-05-10 03:05 · Yahoo
Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab
2026-05-07 20:05 · Yahoo
Ginkgo Bioworks Announces Date of First Quarter 2026 Results Presentation
2026-04-30 12:01 · Yahoo
How The Ginkgo Bioworks (DNA) Story Is Shifting As Analysts Revisit Growth And Risk
2026-03-14 16:08 · Yahoo
Ginkgo Bioworks Launches Ginkgo Cloud Lab, Powered by Autonomous Lab Infrastructure
2026-03-02 13:00 · Yahoo
A Look At Ginkgo Bioworks (DNA) Valuation After Earnings Update And Invaio Collaboration
2026-03-01 08:11 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.